# Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

> **NCT05675683** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 68 (actual)

## Conditions studied

- Metastatic Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Capmatinib

## Key facts

- **NCT ID:** NCT05675683
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05675683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05675683, "Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05675683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*